Rafael Amado - 23 Mar 2022 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
EVP of R&D and CMO
Signature
Veer Bhavnagri as attorney-in-fact for Rafael Amado
Issuer symbol
ALLO
Transactions as of
23 Mar 2022
Net transactions value
$0
Form type
4
Filing time
25 Mar 2022, 17:52:01 UTC
Previous filing
17 Mar 2022
Next filing
19 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +237,358 +74% $0.000000 557,477 23 Mar 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +368,589 $0.000000 368,589 23 Mar 2022 Common Stock 368,589 $9.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter